Slide

Novel, innovative, and targeted medicines to improve outcomes for cancer patients

Amplifying success in immunotherapy

Our mission

Novel, innovative, targeted medicines

When harnessed appropriately, the immune system is an extremely potent and specific endogenous anti-tumor mechanism. Our mission is to develop novel, innovative and targeted medicines that augment endogenous anti-tumor immunity to improve outcomes for patients affected by cancer. 

Our leaders

Pio Tx’s team brings decades of global scientific and commercial expertise, with proven success in therapeutic discovery, preclinical, clinical, regulatory and commercial stages of drug development.

Damien Bates

MD PhD FRACS MBA
Chief Executive Officer & Managing Director

Christopher Chan

PhD

Chief Scientific Officer

Linda Peterson

BSc Grad Cert BA
Chief Operating Officer & Company Secretary

Damien Bates

MD PhD FRACS MBA
Chief Executive Officer & Managing Director

Christopher Chan

PhD

Chief Scientific Officer

Linda Peterson

BSc Grad Cert BA
Chief Operating Officer & Company Secretary

Science

Immunotherapy has revolutionised cancer treatment, however there are challenges to its efficacy.

Pio Tx is developing novel cancer immunotherapies to overcome clinical challenges, to facilitate enhanced combinatorial approaches, and to improve outcomes for patients.